World Journal of Pharmaceutical Sciences
ISSN (Print): 2321-3310; ISSN (Online): 2321-3086
Available online at: https://wjpsonline.com/
Review Article

"BARBITURATES TOXICITY AND OVERDOSE MANAGEMENT: ADVANCES IN CLINICAL TREATMENT"

[1]Sakshitha Mathamshetty, [2]Sridhar Siddiraju, [2]Dr. M. Sudhakar

[1]Pharm.D, Malla Reddy College of Pharmacy (MRCP), Maisammaguda, Telangana, India – 500100.
[2]Department of Pharmaceutical Chemistry, Malla Reddy College of Pharmacy (MRCP), Maisammaguda, Telangana, India – 500100, Email: mathamshettysakshitha@gmail.com.

Received: 18-09-2025 / Revised Accepted: 24-09-2025 / Published: 26-09-2025

ABSTRACT
Recognizing barbiturate toxicity in the absence of obvious symptoms requires a high index of suspicion, especially in patients with a history of barbiturate use or unexplained altered mental status. Serum drug level monitoring, toxicological screening, and extended observation are essential for early detection. Even asymptomatic individuals may deteriorate rapidly, emphasizing the need for clinical vigilance. Even in the absence of clear clinical signs, barbiturate toxicity should remain on the differential diagnosis especially in patients presenting with unexplained CNS depression or a history of use. Vigilant assessment with lab confirmation and extended monitoring is key, as clinical deterioration can be both silent and sudden.

Keywords: Barbiturates; Toxicity; Overdose; Extracorporeal elimination; Hemodialysis; Critical care; Sedative poisoning; Phenobarbital; Thiopental; Neurotoxicity; Decontamination.

INTRODUCTION
TOPICAL DRUG DELIVERY SYSTEM
Barbiturates are a class of central nervous system (CNS) depressants that gained prominence during the mid-20th century due to their effectiveness as sedatives, hypnotics, and anticonvulsants. Though their clinical application has significantly declined with the advent of safer alternatives like benzodiazepines, certain agents such as phenobarbital and thiopental are still employed in specific medical situations, including seizure control, induction of anesthesia, and therapeutic coma induction. Despite their reduced therapeutic use, barbiturates remain clinically significant—particularly in toxicology—owing to their narrow therapeutic range and high overdose risk. Toxicity from barbiturates manifests as deep CNS depression, marked respiratory suppression, hypotension, and, in severe instances, coma. Overdose scenarios may be intentional or accidental, and patient outcomes are strongly influenced by variables such as the specific agent involved, dosage consumed, concurrent substance use, and the timeliness of medical intervention. Delayed recognition and treatment often correlate with increased mortality in critical cases. Over the years, progress in emergency and critical care has led to improved approaches for managing barbiturate poisoning. Enhanced supportive care, advancements in detoxification methods, and neuroprotective strategies have collectively contributed to better survival rates and neurological recovery. In particular, extracorporeal techniques like hemodialysis, hemoperfusion, and forced alkaline diuresis have proven effective, especially in overdoses involving long-acting barbiturates like phenobarbital [1,2].

DEFINITION:
Barbiturates belong to a class of drugs that act as central nervous system depressants and are categorized under sedative-hypnotics. They exert their pharmacological effects by potentiating the action of gamma-aminobutyric acid (GABA), the brain's primary inhibitory neurotransmitter. The resultant effect is a reduction in neuronal excitability, leading to sedation, muscle relaxation, and sleep induction

Address for Correspondence: Sakshitha Mathamshetty, Pharm.D, Malla Reddy College of Pharmacy (MRCP), Maisammaguda, Telangana, India – 500100, mathamshettysakshitha@gmail.com.

How to Cite this Article: Sakshitha Mathamshetty, BARBITURATES TOXICITY AND OVERDOSE MANAGEMENT: ADVANCES IN CLINICAL TREATMENT, World J Pharm Sci 2025; 13(03): 165-171; https://doi.org/10.54037/WJPS.2022.100905

Key Features and Clinical Applications: Historically, barbiturates have served a wide array of clinical roles, such as:

Anticonvulsant Therapy: Effective in controlling specific types of epileptic seizures, particularly generalized tonic-clonic and partial seizures.

Preoperative and Procedural Sedation: Utilized to induce sedation before surgeries or diagnostic procedures to reduce patient anxiety and discomfort.

Anxiolytic Use: Occasionally prescribed for acute episodes of anxiety, though now largely replaced by safer alternatives like benzodiazepines.

Hypnotic Treatment: Previously employed in the management of insomnia by promoting sleep onset and continuity [3].

II. TYPES:

Barbiturate types are distinguished by the length of their action, which dictates their therapeutic window and onset speed.

1. Ultra-short acting barbiturates, such as thiopental and methohexital, produce effects within seconds to minutes and wear off quickly. These drugs are primarily employed for inducing anesthesia or managing acute seizures due to their rapid onset.
2. Short-acting agents like pentobarbital and secobarbital usually exert effects for approximately three to four hours. Once commonly prescribed for sleep disorders and as sedatives, they are now seldom used due to the risk of dependence and the emergence of safer medications.
3. Intermediate-acting agents, like amobarbital and butabarbital, exert their effects for approximately 6 to 8 hours. These were formerly utilized for pre-anesthetic sedation or mild insomnia but have fallen out of favor in contemporary practice.
4. Long-acting barbiturates, such as phenobarbital and mephobarbital, can remain effective for over 12 hours. Owing to their prolonged action and relatively lower abuse potential, they are still widely used for controlling chronic seizure disorders, particularly in epilepsy management.

- **Mechanism of Action:** Barbiturates exert their pharmacological effects by potentiating the function of gamma-aminobutyric acid (GABA), the brain's chief inhibitory neurotransmitter, leading to central nervous system depression.
- **Detailed Mechanism:** These drugs bind to the GABA-A receptor complex, enhancing the duration of chloride ion channel opening. This results in increased neuronal inhibition and decreased excitability, thereby promoting sedation, hypnosis, and anticonvulsant effects [4,5].



Figure.1 Barbiturate types

DIFFERENT BRANDS OF BARBITURATES:

Table.1 different brands of barbiturates

BRAND NAME	GENERIC NAME	INITIAL DOSE	MAXIMUM DOSE	OVERDOSE
Luminal	Phenobarbital	30-60mg/kg	400mg/kg	1-2grams: severe toxicity, coma, respiratory depression.
Nembutal	Pentobarbital	50-100mg/kg	200mgkg	500mg: severe toxicity, respiratory depression, coma.
Seconal	Secobarbital	100mg/kg	200mg/kg	300mg: severe toxicity, respiratory depression, coma.
Amytal	amobarbital	65-200mg/kg	400mg/kg	500mg: severe toxicity, respiratory depression, coma.

Figure.2 DIFFERENT BRANDS OF BARBITURATES [29]

IV.RECOMMENDED DOSING STRATEGIES FOR BARBITURATES:

Fundamental Guidelines:

1. Initiate with a conservative dose: Always begin with the lowest dose that is likely to be effective to limit potential side effects.

2. Increase dose cautiously: Dosage adjustments should be made slowly and only as needed to reach the desired clinical effect.

- Monitor for adverse effects: Continuous assessment is essential to detect early signs of toxicity, including sedation, cognitive impairment, or depressed respiration.

Dosing Recommendations by Agent:

a) Phenobarbital:

- Recommended starting dose: 30–60 mg per day.

- Usual maintenance range: 1–3 mg/kg/day.

b) Pentobarbital:

- Typical initial dose: 50–100 mg daily.

- Maximum allowable dose: 200 mg per day [6,7,8]

• Barbiturates: Appropriate Candidates for Use:

Barbiturates are prescribed selectively and only in specific medical situations where other interventions have not been successful:

1. Treatment-Resistant Seizures: Patients suffering from epilepsy or other seizure disorders that do not respond to standard antiepileptic medications may be considered for barbiturate therapy.
2. Severe Insomnia (Short Duration): For individuals experiencing intense sleep disturbances unrelieved by other sleep aids, barbiturates may be prescribed for brief use—typically less than two weeks.
3. Pre-Surgical Sedation: These drugs may be administered before surgical procedures to calm the patient and induce sedation.

Situations Where Barbiturates Are Not Recommended:

1. Pregnant or Breastfeeding Individuals: Barbiturates pose significant risks to fetal development and may be passed to infants through breast milk, making them unsuitable during pregnancy or lactation.
2. Substance Abuse History: Those with a background of drug or alcohol abuse are at increased risk of dependence and are typically advised against barbiturate use.
3. Serious Liver or Lung Conditions: Patients with advanced liver disease or compromised respiratory function should not use barbiturates due to their depressant effects on vital systems [9,10,11].

V. PHARMACOKINETIC PROFILE OF BARBITURATES:

Barbiturates are a class of CNS depressants widely utilized for their sedative, hypnotic, anesthetic, and anticonvulsant properties. Their pharmacokinetic behavior varies considerably among different agents, particularly based on lipid solubility, rate of onset, and duration of therapeutic effect.

1. Absorption: Barbiturates are effectively absorbed from the gastrointestinal tract following oral administration, largely owing to their lipophilic nature. Long-acting compounds like phenobarbital demonstrate efficient oral absorption.

- Maximum plasma concentrations are typically achieved within 30–60 minutes for short-acting agents and 1–2 hours for longer-acting formulations.

2. Distribution: Barbiturates exhibit widespread distribution throughout body tissues, with rapid CNS penetration facilitated by their lipid solubility.

-The volume of distribution (Vd) is influenced by lipophilicity:

a) Thiopental has a high Vd due to extensive fat solubility.

b) Phenobarbital, being less lipophilic, shows a lower Vd.

c) These drugs readily cross the placental barrier and can be secreted into breast milk.

3. Protein Binding: The extent to which barbiturates bind to plasma proteins differs by compound:

a) Phenobarbital demonstrates moderate binding (~20–45%).

b) Thiopental is highly bound to plasma proteins (around 80%), affecting both distribution and free drug levels.

4. **Metabolism:** Barbiturates are primarily metabolized in the liver via the cytochrome P450 enzyme system (CYP450). Phenobarbital undergoes slow hepatic metabolism and also induces its own metabolism over time (a process known as autoinduction). Thiopental is rapidly redistributed from the CNS to peripheral tissues, followed by hepatic biotransformation.
5. **Elimination:** Renal excretion of unchanged barbiturate varies: Unmetabolized barbiturates make up a very small proportion of what is expelled through the urinary system. However, phenobarbital is an exception, as a significant proportion is excreted renally, making it suitable for elimination enhancement via urinary alkalinization in overdose situations [12,13,14].

VI. BARBITURATES TOXICITY: SYSTEMIC EFFECTS ON THE HUMAN BODY:

Barbiturate toxicity impacts numerous body systems due to its potent central nervous system (CNS) depressant effects. The severity of clinical manifestations depends on the amount ingested and duration of exposure, with symptoms ranging from mild drowsiness to deep coma and potential multi-organ dysfunction.

1. Central Nervous System (CNS): Barbiturates potentiate the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) via GABA-A receptors, suppressing neuronal excitability. Toxic levels may cause:

- Drowsiness, disorientation, and impaired speech.
- Unsteady gait (ataxia), involuntary eye movements (nystagmus).
- Deep unconsciousness or suppression of brainstem reflexes in critical toxicity.



Figure.3 SYMPTOMS OF BARBITURATES TOXICITY[28]

2. Respiratory System: These drugs inhibit the brainstem centers responsible for breathing, resulting in:

- Decreased respiratory drive or cessation of breathing.
- Accumulation of carbon dioxide causing respiratory acidosis.
- Requirement for artificial ventilation in severe presentations.

3. Cardiovascular System: Barbiturates can impair heart and vascular function, leading to:

- Reduced arterial pressure caused by dilated blood vessels and weakened myocardial performance.
- Slowing of heart rate (bradycardia).
- Circulatory collapse in extreme overdoses.

4.Renal System: Although primarily cleared by the liver, barbiturate toxicity may affect the kidneys via:

- Acute tubular injury due to hypotensive episodes or muscle breakdown (rhabdomyolysis).
- Reduced drug clearance in pre-existing kidney dysfunction, especially with long-acting agents [15,16].

Figure.3 Symptoms

5. Liver (Hepatic) Effects: Liver involvement in toxicity includes:

- Induction of hepatic enzymes, particularly with chronic use.
- Occasional cases of liver cell damage at high toxic levels.

6. Muscular and Skeletal System: Neuromuscular symptoms in toxicity may include:

- Loss of muscle tone (flaccidity).
- Breakdown of skeletal muscle (rhabdomyolysis), often related to prolonged immobility or coma.

7. Skin and Eye Manifestations: Dermatologic and ocular findings can occur, such as:

- Formation of blistering skin lesions ("barbiturate blisters") during extended comatose states [17,18,19].

VII. UNDERLYING CAUSES OF APPARENT OVERDOSE WITHOUT OBSERVABLE TOXIC EFFECTS:

• Dose Taken Exceeds Normal but Remains Below Individual Toxic Threshold: Although the ingested amount may be above the standard therapeutic dosage, it might still fall short of the toxic level for that specific person. This discrepancy can be explained by intrinsic biological variation—factors such as body mass, enzymatic activity, receptor responsiveness, and genetic makeup can all influence the body's reaction to a substance.

• Established Drug Tolerance from Chronic Exposure: Long-term or habitual users of certain medications—especially central nervous system depressants like opioids, barbiturates, or benzodiazepines—often develop pharmacodynamic tolerance. This adaptation allows their bodies to withstand higher serum concentrations with minimal or no adverse symptoms, masking toxicity that would otherwise be evident in naïve users.

• Prolonged or Altered Absorption Due to Drug Formulation: Medications formulated for delayed or prolonged release—such as sustained-release (SR), controlled-release (CR), or enteric-coated versions—result in slower absorption into the bloodstream. As a result, the expected toxic symptoms may be postponed, leading to a deceptive clinical picture early on.

- Examples include theophylline ER, venlafaxine XR, and elemental iron in slow-release tablets.

• Enhanced Drug Elimination through Accelerated Metabolism: In some individuals, especially those with genetic variants in hepatic enzyme systems (e.g., cytochrome P450 isoenzymes), the drug may be metabolized at a significantly faster rate than average. This rapid breakdown, combined with efficient renal or hepatic clearance, may result in a quick reduction of plasma drug concentration, thereby minimizing potential toxicity.

• Limited Bioavailability after Ingestion: A drug may be poorly absorbed from the gastrointestinal tract due to intrinsic chemical properties or due to extrinsic factors such as emesis, diarrhea, or the presence of adsorptive substances like activated charcoal. In such scenarios, a large oral dose may result in only a minimal amount reaching the systemic circulation.

- A classic example is oral vancomycin, which remains largely confined to the gut lumen.

• Neutralizing Interactions or Concurrent Protective Medications: Certain medications or medical interventions administered at or around the time of ingestion may block, reverse, or reduce the effects of the ingested drug. For instance, naloxone administration in opioid exposure can instantly reverse central respiratory depression, and early activated charcoal can bind many drugs before absorption, reducing toxicity significantly.

• Psychological Factors or Fabricated Overdose Reports: In some cases, the overdose may be exaggerated or entirely fictitious—patients might claim to have taken a dangerously high dose for reasons such as attention-seeking behavior (e.g., factitious disorder or malingering), manipulation, or psychiatric distress. Despite their claims, either no drug was ingested or the dose was insufficient to produce toxic effects.

• Deactivated, Expired, or Degraded Drug Product: Medications that have passed their shelf life or have been exposed to degrading environmental conditions (e.g., heat, moisture, sunlight) may lose potency. Thus, a consumed dose might have significantly less active drug than intended, rendering it ineffective and non-toxic despite the perceived overdose.

• Extensive First-Pass Hepatic Inactivation: Some compounds undergo substantial first-pass metabolism in the liver after being absorbed through the gut. As a result, the amount of active drug that actually reaches systemic circulation is dramatically reduced.

- This is common with drugs like propranolol and morphine, which are metabolized extensively before exerting systemic effects.

• Early Medical Management and Timely Decontamination: Immediate medical interventions such as induced emesis, gastric lavage, activated charcoal, or antidote administration can significantly curtail drug absorption or counteract its effects.

- Supportive therapy, including IV fluids, oxygen supplementation, or symptomatic treatment, may also prevent the development of overt toxicity even when a large dose has been ingested[20,21,22].

VIII. MANAGEMENT OF BARBITURATE OVERDOSE TOXICITY: CONTEMPORARY CLINICAL APPROACHES:-

1. Immediate Stabilization and Assessment: Airway, Breathing, and Circulation (ABC). Ensure airway patency—patients with decreased consciousness may require endotracheal intubation. Provide assisted ventilation in cases of significant respiratory depression. Address hypotension using intravenous fluids; administer vasopressors if perfusion remains inadequate.

- Physiological and Neurological Monitoring: Initiate continuous monitoring of vital signs including ECG, blood pressure, oxygen saturation, and core temperature. Evaluate neurological status regularly using the Glasgow Coma Scale (GCS) to guide clinical decisions.

2. Gastrointestinal Decontamination: Single-dose activated charcoal (1 g/kg, maximum 50 g) is recommended within 1–2 hours post-ingestion when the airway is protected.

- For delayed presentations or ingestion of long-acting formulations like phenobarbital, multiple-dose activated charcoal (MDAC) may improve elimination through interruption of enterohepatic recirculation [23,24].

3. Supportive Measures: Maintain normal body temperature as hypothermia frequently accompanies barbiturate poisoning. Prevent secondary complications such as aspiration, rhabdomyolysis, and pressure sores through supportive nursing care.

- Avoid the use of central nervous system stimulants unless clinically indicated; allow time for natural drug clearance under close observation.

4. Strategies for Enhanced Drug Elimination:

a) Urinary Alkalinization:

Particularly effective for phenobarbital, a weak acid. To boost drug clearance via the kidneys, intravenously administer sodium bicarbonate and maintain the urine's pH above 7.5. Monitor serum potassium closely, as hypokalemia can compromise the efficacy of alkalinization.

b) Hemodialysis:

Consider in patients with: Life-threatening toxicity, Renal dysfunction, Persistent hypotension, Excessively high serum barbiturate concentrations. Phenobarbital is especially suitable for dialysis due to its low protein binding and hydrophilic nature.

c) Hemoperfusion:

Although less common in modern practice, charcoal hemoperfusion remains effective for removing lipid-soluble barbiturates. It may outperform dialysis for short-acting compounds like secobarbital but is limited by availability and technical resources.

5. Prognosis and Ongoing Monitoring: Full recovery may be prolonged, especially following overdose with long-acting agents.

- Continuous EEG monitoring is valuable in comatose patients to detect non-convulsive seizures or suppressed cerebral activity. Monitor hepatic and renal function regularly in severe or prolonged cases.

6. Emerging and Investigational Therapies:

a) Lipid Emulsion Therapy: Under investigation for its potential to bind and sequester lipophilic barbiturates; currently limited to experimental settings.

b) Neuroprotective Interventions: Approaches such as therapeutic hypothermia and antioxidant administration are being studied for their potential to reduce neurologic injury in barbiturate-related coma [25,26,27].

IX. CONCLUSION:

Barbiturate toxicity presents a challenging clinical scenario, as these agents can exert profound effects across multiple body systems. Primarily acting as central nervous system depressants, they can induce critical conditions such as suppressed respiration, cardiovascular compromise, and deep coma when consumed in toxic amounts. Interestingly, some individuals may ingest large doses without overt toxic effects, often due to developed tolerance, metabolic variations, or sub-toxic drug levels.

The toxic potential of barbiturates is strongly influenced by their pharmacokinetic properties—particularly lipid solubility, protein-binding affinity, metabolic breakdown in the liver, and renal excretion. Agents with ultra-short duration, like thiopental, act swiftly and are redistributed quickly, reducing their lasting toxicity. In contrast, long-acting compounds like phenobarbital tend to accumulate in the system, increasing the risk of

extended adverse effects. The management of barbiturate toxicity has progressed substantially. While core lifesaving measures such as airway protection, ventilatory support, and cardiovascular stabilization remain central, newer strategies now enhance patient care. These include advanced monitoring systems, extracorporeal elimination techniques like hemodialysis—especially effective for phenobarbital—and urinary alkalinization with sodium bicarbonate to improve renal clearance. Prompt recognition of symptoms and individualized treatment planning are vital to improving patient prognosis.

In essence, successfully managing barbiturate toxicity hinges on an integrated approach—one that encompasses an in-depth knowledge of systemic effects, individualized pharmacokinetics, and the application of modern therapeutic innovations.

X. REFERENCES:

1. Goodwin FK, Bunney WE. Phenobarbital: Clinical pharmacology and use. Am J Psychiatry. 1968;124(9):1232–8.
2. Klowak M, Dobler CC, McDonald CF, Irving LB. Sedative medications: clinical uses and toxicology. Med J Aust. 2020;213(5):220–6.
3. Dawson AH, Buckley NA. Pharmacological management of barbiturate poisoning. Toxicol Rev. 2004;23(2):105–12.
4. Van Nostrand D, Feldman JM. Pharmacology of anesthetic agents. Anesth Clin North Am. 2001;19(2):251–70.
5. 5.Stoelting RK, Hillier SC. Pharmacology and Physiology in Anesthetic Practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
6. Katzung BG. Basic and clinical pharmacology. 14th ed. New York: McGraw-Hill Education; 2020.
7. American Pain Society. Principles of analgesic use in the treatment of acute pain and cancer pain. 7th ed. Chicago: APS; 2016.
8. FDA. Barbiturates. In: Drugs@FDA. Silver Spring, MD: FDA; 2020.
9. Katzung BG. Basic and clinical pharmacology. 14th ed. New York: McGraw-Hill Education; 2020.
10. National Institute for Health and Care Excellence. Insomnia - management of insomnia in adults. London: NICE; 2020.
11. American Society of Anesthesiologists. Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures. Anesthesiology. 2020;132(3):496-514
12. Katzung BG, Vanderah TW. Basic and Clinical Pharmacology. 15th ed. New York: McGraw-Hill; 2021.
13. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill; 2018.
14. O'Neil MJ, editor. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals. 15th ed. Cambridge: Royal Society of Chemistry; 2013.
15. Isbister GK, Dawson A, Whyte IM. Barbiturate poisoning: a review. Clin Toxicol (Phila). 2003;41(3):223–233.
16. Brent J, Wallace KL, Burkhart KK, Phillips SD, Donovan JW. Critical Care Toxicology: Diagnosis and Management of the Critically Poisoned Patient. Philadelphia: Elsevier; 2005.
17. Sporer KA. Acute barbiturate overdose. J Emerg Med. 1993;11(3):299–308.
18. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS. Goldfrank's Toxicologic Emergencies. 10th ed. New York: McGraw-Hill; 2015.
19. Olson KR. Poisoning and Drug Overdose. 6th ed. New York: McGraw-Hill Education; 2011.
20. Goldfrank LR, Flomenbaum NE, Lewin NA, et al. Goldfrank's Toxicologic Emergencies. 11th ed. McGraw-Hill Education; 2019.
21. Nelson LS, Howland MA, Lewin NA, et al. Goldfrank's Manual of Toxicologic Emergencies. 2nd ed. McGraw-Hill; 2015.
22. Dart RC. Medical Toxicology. 3rd ed. Lippincott Williams & Wilkins; 2004.
23. 23.Olson KR. Poisoning & Drug Overdose. 7th ed. New York: McGraw-Hill Education; 2018. p. 80–85.
24. 24.Vale JA, Proudfoot AT. How useful are antidotes in clinical toxicology? A critical review of the evidence. Br J Clin Pharmacol. 1993;35(4):327–332.
25. 25.Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS. Goldfrank's Toxicologic Emergencies. 10th ed. New York: McGraw-Hill; 2015.
26. 26.Shannon MW, Borron SW, Burns MJ. Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose. 4th ed. Saunders Elsevier; 2007.
27. 27.Tenenbein M. The role of extracorporeal techniques in the treatment of poisoned patients. Clin Toxicol (Phila). 2001;39(3):185–190.
28. Addiction resource. Barbiturates toxicity infographic (Internet). AddictionResources.com;(Downloaded image).
29. We Level Up New Jersey. Image. Available from welevelupnj.com.